Key result
Atorvastatin /day did not affect plasma concentrations of C-type Natriuretic Peptide (CNP) products or Endothelin-1 in males with or without symptomatic coronary artery disease.
Why the study?
Although statins acutely modulate CNP and ET-1 in human cultured endothelial cells in vitro, whether these actions are reflected in vivo is unknown.
Does atorvastatin 40 mg daily modulate plasma C-type Natriuretic Peptides and Endothelin-1 in statin-naive males with and without symptomatic coronary artery disease?
Cohort (n=66)
Open-label
No
Does atorvastatin 40 mg daily modulate plasma C-type Natriuretic Peptides and Endothelin-1 in statin-naive males with and without symptomatic coronary artery disease?
Conventional doses of atorvastatin do not affect plasma CNP products or ET-1 in vivo, suggesting that elevated CNP after cardiac injury results from regulated changes in clearance rather than enhanced production.
Answers are grounded in this paper and cite their sources.
No effect of atorvastatin on CNP or ET-1 expected in CAD; leaves open CNP regulation via clearance post-injury.
C-type Natriuretic Peptide (CNP) and Endothelin-1 (ET-1) have reciprocal roles in maintaining vascular homeostasis and are acutely modulated by statins in human cultured endothelial cells. Whether these actions of statins in vitro are reflected in studies in vivo is unknown. In a prospective study of 66 subjects with or without post- acute coronary syndrome (ACS), plasma concentrations of bioactive CNP and bio-inactive aminoterminal proCNP (NTproCNP), ET-1, B-type Natriuretic Peptide (BNP) and high sensitivity C Reactive Protein (hsCRP) were measured together with lipids before and at intervals of 1, 2 and 7 days after commencing atorvastatin 40 mg/day - and for a further period of 6months in those with ACS. Plasma lipids fell significantly in all subjects but plasma CNP, NTproCNP and ET-1 were unchanged by atorvastatin. In ACS, baseline hsCRP, BNP and CNP but not NTproCNP or ET-1 were significantly raised compared to values in age-matched controls. The ratio of NTproCNP to CNP was significantly lower in ACS throughout the study and was unaffected by statin therapy. We conclude that conventional doses of atorvastatin do not affect plasma CNP products or ET-1. Elevated CNP after cardiac injury likely results from regulated changes in clearance, not enhanced production.
No takes yet. Share an insight, caveat, or question.
Prickett et al. (2020) conducted a cohort in Coronary artery disease (n=66). Atorvastatin vs. Baseline (pre-treatment) was evaluated on Change in plasma concentrations of CNP, NTproCNP, and ET-1. Atorvastatin /day did not affect plasma concentrations of C-type Natriuretic Peptide (CNP) products or Endothelin-1 in males with or without symptomatic coronary artery disease.
Synapse has enriched 10 related papers. Consider them for comparative context: